One of Inhibrx Biosciences’ antibody candidates has shown encouraging early efficacy in colorectal cancer. But its safety is under scrutiny after a patient enrolled in the Phase 1 trial died.
The biotech’s ozekibart plus FOLFIRI ...
↧
